— Know what they know.
Not Investment Advice

NSPR NASDAQ

InspireMD, Inc.
1W: -16.7% 1M: -25.9% 3M: -42.2% YTD: -46.2% 1Y: -57.6% 3Y: -31.0% 5Y: -79.0%
$1.00
-0.00 (-0.01%)
 
Weekly Expected Move ±8.7%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Medical - Devices · Alpha Radar Sell · Power 32 · $46.8M mcap · 27M float · 0.976% daily turnover · Short 27% of daily vol
Smart Money Score
Watch 25
Insider+$0.4M
Congress
ETF Holdings
Key Statistics
Market Cap$46.8M
52W Range1-2.93
Volume271,328
Avg Volume262,854
Beta0.82
Dividend
Analyst Ratings
6 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOMarvin L. Slosman
Employees85
SectorHealthcare
IndustryMedical - Devices
IPO Date2011-04-12
4 Menorat Hamaor Street
Miami 6744832
IL
888 776 6804
About InspireMD, Inc.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Recent Insider Trades

NameTypeSharesPriceDate
Stuka Paul P-Purchase 5,000 $1.15 2026-05-14
Stuka Paul P-Purchase 10,000 $1.16 2026-05-13
Slosman Marvin P-Purchase 21,000 $1.20 2026-05-12
Stuka Paul P-Purchase 10,000 $1.19 2026-05-11
Stuka Paul P-Purchase 65,626 $1.16 2026-05-08

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms